Clinical Pharmacology & Biopharmaceutics
Open Access

CRISPR in drug discovery; Gene editing in medicine; CRISPR-based therapeutics; precision medicine and CRISPR; Genome engineering for drug development; CRISPR screening for drug targets; Gene therapy innovations; Personalized genetic medicine; CRISPR and rare disease treatments; Ethical and regulatory challenges in CRISPR

Description

CRISPR technology has emerged as a game-changing tool in pharmaceutical research, offering a precise and efficient method for gene editing. Unlike traditional drug discovery methods, which rely on chemical compounds and small molecules, CRISPR enables direct manipulation of the genome to identify disease mechanisms and develop targeted therapies.

One of the key applications of CRISPR in drug discovery is in functional genomics, where researchers use CRISPR-based screening to pinpoint critical genes responsible for disease progression. This helps in identifying novel drug targets with higher specificity. CRISPR has also been instrumental in creating disease models in vitro and in vivo, allowing for faster preclinical testing of new drug candidates.

Beyond target discovery, CRISPR is playing a crucial role in the development of gene therapies for inherited disorders such as sickle cell anemia, cystic fibrosis, and muscular dystrophy. In cancer treatment, CRISPR-based approaches are being explored for personalized immunotherapies, such as enhancing T-cell function for targeted tumor destruction. Additionally, CRISPR is being used in antiviral research to develop potential cures for infections like HIV and hepatitis B.

Despite its transformative potential, CRISPR-based drug discovery faces challenges, including off-target effects, ethical considerations, and regulatory hurdles. Ensuring the safety and efficacy of gene-edited therapies requires rigorous validation and clinical trials. However, with continued advancements, CRISPR holds the promise of ushering in a new era of precision medicine, where treatments are tailored to the genetic makeup of individual patients, leading to more effective and safer therapeutic solutions.

Discussion

The integration of CRISPR technology into drug discovery and precision medicine has significantly advanced the development of targeted therapies. Unlike conventional drug development, which often relies on broad-spectrum approaches, CRISPR enables precise genetic modifications, allowing researchers to better understand disease mechanisms and identify novel drug targets.

CRISPR-based genome-wide screening has revolutionized the identification of disease-related genes and pathways. By knocking out or modifying specific genes in cell and animal models, researchers can assess their roles in disease progression, leading to more precise drug targets. This has been particularly impactful in oncology, where CRISPR has helped identify key mutations driving tumor growth, enabling the development of targeted cancer therapies.

CRISPR technology is enhancing high-throughput drug screening by creating genetically modified cell lines and animal models that accurately mimic human diseases. These models enable rapid assessment of drug efficacy and toxicity, reducing the reliance on traditional, less predictive methods. Additionally, CRISPR-based editing allows for the development of synthetic lethality approaches, where specific gene alterations make cancer cells more susceptible to drug treatments.One of the most promising applications of CRISPR is in gene therapy, where it is being used to correct genetic mutations responsible for inherited disorders. Diseases such as sickle cell anemia, cystic fibrosis, and muscular dystrophy are at the forefront of CRISPR-based therapeutic development. Additionally, CRISPR holds potential in personalized medicine, where treatments can be tailored to an individual's genetic profile, leading to higher efficacy and fewer side effects.

Conclusion

CRISPR technology is transforming drug discovery and therapeutic development by enabling precise gene editing, enhancing target identification, and facilitating the development of personalized treatments. Its applications extend across various medical fields, from cancer therapy to genetic disorder correction and antiviral drug research. Despite existing challenges, including ethical concerns, off-target effects, and delivery limitations, ongoing advancements in CRISPR technology are likely to overcome these obstacles, paving the way for safer and more effective gene-based therapies. As CRISPR continues to evolve, it holds immense promise for shaping the future of precision medicine, offering new hope for previously untreatable diseases and redefining the landscape of pharmaceutical innovation.

References

1.  
2. Allen TM, Cullis PR. (2004) Drug delivery systems: entering the mainstream. Science 303: 1818-1822.  

   Indexed at, Google Scholar, Crossref

3.  
4. Chakraborty C, Pal S, Doss GP, Wen Z, Lin C (2013) Nanoparticles as “smart” pharmaceutical delivery. Frontiers in Bioscience 18: 1030-1050.  

   Indexed at, Google Scholar, Crossref

5.  
6. Langer R (1990) New methods of drug delivery. Science 249: 1527-1533.  

   Indexed at, Google Scholar, Crossref

7.  
8. Wolff JA (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.  

   Indexed at, Google Scholar, Crossref

9.  
10. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1991) Pancreatic extracts in the treatment of diabetes mellitus: preliminary report 1922. Canadian Medical Association Journal 145: 1281-1286.  

    Indexed at, Google Scholar

11.  
12. Pickup J (1986) Human insulin. British Medical Journal 292: 155-157.  

    Indexed at, Google Scholar, Crossref

13.  
14. Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007 an update. Journal of Gene Medicine 9: 833-842.  

    Indexed at, Google Scholar, Crossref

15.  
16. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J (2013) Gene therapy clinical trials worldwide to an update. Journal of Gene Medicine 15: 65-77.  

    Indexed at, Google Scholar, Crossref

17.  
18. You Y, Lai X, Pan Y (2022) Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Target Ther 7  

    Indexed at, Google Scholar, Crossref

19.  
20. Golriz Khatami S, Mubeen S, Bharadhwaj VS, Kodamullil AT, Hofmann-Apitius M, et al. (2021) Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures. NPJ Syst Biol Appl 7  

    Indexed at, Google Scholar, Crossref